Means and methods for the recruitment and identification of stem cells

1. A method for enhancing recruitment of stem cells and/or progenitor cells selected from the group consisting of bone marrow stem cells, bone marrow progenitor cells, and combinations thereof, said method comprising:

identifying a subject suffering from a disease or condition that would benefit from enhanced recruitment of stem cells and/or progenitor cells;

introducing to the subject a plasmin modulator, wherein the plasmin modulator is a plasmin activator selected from the group consisting of plasmin, plasminogen, chimeric plasminogen, tissue-type plasminogen activator, tenecteplase, urokinase-type plasminogen activator, alpha-enolase, staphylokinase, streptokinase, sulodexide, T-686 ((3E,4E)-3-benzylidene-4-(3,4,5-trimethoxy-benzylidene) pyrrolidine-2,5-dione), an antibody against plasminogen activator inhibitor, an antibody against alpha-2-antiplasmin, and microplasmin; and

introducing to the subject a myelopoietic agent selected from the group consisting of G-CSF, M-CSF, IL- 3 , SCF, VEGF, VEGF-B, VEGF-C, VEGF-D, PlGF, PDGF-A, PDGF-C, PDGF-D, erythropoietin, and Flt3-ligand;

so as to enhance recruitment of the stem cells and/or progenitor cells.

2. The method according to claim 1 , wherein said stem cells and/or progenitor cells comprise a hematopoietic cell.

3. The method according to claim 1 , wherein said stem cells and/or progenitor cells comprise an endothelial progenitor cell.

4. The method according to claim 1 , wherein the disease or condition is selected from the group consisting of ischemic diseases, lung injury, stroke, muscle degeneration, muscle dystrophy, liver injury, kidney injury, ischemic limb disease, ischemic heart disease, and acute myocardial infarction.

5. A method for enhancing recruitment of stem cells and/or progenitor cells used in patients, the method consisting of:

introducing a pharmaceutical composition to a patient having a disorder selected from the group consisting of: leukopenia or pancytopenia caused by chemotherapy, leukopenia or pancytopenia caused by bone marrow transplantation, congenital leukopenia, congenital neutropenia, idiopathic neutropenia, and AIDS, wherein the pharmaceutical composition comprises:

a plasmin activator selected from the group consisting of plasmin, plasminogen, chimeric plasminogen, tissue-type plasminogen activator, tenecteplase, alpha-enolase, staphylokinase, streptokinase, sulodexide, T-686 ((3E,4E)-3-benzylidene-4-(3,4,5-trimethoxy-benzylidene) pyrrolidine-2,5-dione), an antibody against plasminogen activator inhibitor, an antibody against alpha-2-antiplasmin, and microplasmin; and

a suitable pharmaceutical excipient,

so as to enhance recruitment of stem cells and/or progenitor cells, thereby treating the patient.

6. The method according to claim 5 , wherein said stem cell and/or progenitor cell comprises a hematopoietic cell.

7. The method according to claim 5 , wherein said stem cell and/or progenitor cell comprises an endothelial progenitor cell.

8. A method for enhancing recruitment of stem cells and/or progenitor cells used in patients having a disorder selected from the group consisting of leukopenia or pancytopenia caused by chemotherapy, leukopenia or pancytopenia caused by bone marrow transplantation, congenital leukopenia, congenital neutropenia, idiopathic neutropenia, AIDS, and combinations of any thereof, the method comprising:

introducing a plasmin-modulator to stem cells and/or progenitor cells so as to enhance recruitment of bone marrow stem cells and/or bone marrow progenitor cells, wherein the plasmin modulator is a plasmin activator selected from the group consisting of plasmin, plasminogen, chimeric plasminogen, tissue-type plasminogen activator, tenecteplase, urokinase-type plasminogen activator, alpha-enolase, staphylokinase, streptokinase, sulodexide, T-686 ((3E,4E)-3-benzylidene-4-(3,4,5-trimethoxy-benzylidene) pyrrolidine-2,5-dione), an antibody against plasminogen activator inhibitor, an antibody against alpha-2-antiplasmin, and microplasmin; and

introducing to said stem cells a myelopoietic agent selected from the group consisting of G-CSF, M-CSF, GM-CSF, IL- 3 , SCF, VEGF, VEGF-B, VEGF-C, VEGF-D, PlGF, PDGF-A, PDGF-C, PDGF-D, erythropoietin, and Flt3-ligand;

so as to enhance recruitment of stem cells and/or progenitor cells, thereby treating the disorder.

9. A method for enhancing recruitment of stem cells and/or progenitor cells used in patients having a disorder selected from the group consisting of leukopenia or pancytopenia caused by chemotherapy, leukopenia or pancytopenia caused by bone marrow transplantation, congenital leukopenia, congenital neutropenia, idiopathic neutropenia, AIDS, and combinations of any thereof, the method comprising:

introducing a plasmin-modulator to the stem cells and/or progenitor cells so as to enhance recruitment of bone marrow stem cells and/or bone marrow progenitor cells, wherein the plasmin-modulator is a plasmin activator selected from the group consisting of plasmin, plasminogen, chimeric plasminogen, tissue-type plasminogen activator, tenecteplase, alpha-enolase, staphylokinase, streptokinase, sulodexide, T-686 ((3E, 4E)-3-benzylidene-4-(3, 4, 5-trimethoxy-benzylidene) pyrrol- idine-2, 5-dione), an antibody against plasminogen activator inhibitor, an antibody against alpha-2-antiplasmin, and microplasmin;

so as to enhance recruitment of stem cells and/or progenitor cells, thereby treating the patient.

10. The method according to claim 9 , wherein said stem cell and/or progenitor cell comprises a hematopoietic cell.

11. The method according to claim 9 , wherein said stem cell and/or progenitor cell comprises an endothelial progenitor cell.